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Abstract
Placental hCG and pitutary LH transduce signals in target tissues through a common receptor (LHCGR). We
demonstrate that recombinant LHCGR proteins which include the hormone-binding domain are secreted from
transfected cells and that natural LHCGR is also secreted from human placental explants. LHCGR recombinant
proteins representing varying lengths of the N-terminal extracellular domain were expressed in Chinese Hamster
Ovary cells in suspension culture. Secretion was minimal up to 72h but by 96h 24-37% of the LHCGR had been
released into the culture medium. The secreted proteins were folded and sensitive to glycosidases suggesting
N-linked glycosylation. Secretion was independent of recombinant size and was mediated via structurally defined
membrane vesicles (50-150nm). Similarly cultured human early pregnancy placental explants also released LHCGR
via microvesicles. These studies provide the first experimental evidence of the possible mechanistic basis of the
secretion of LHCGR.
Background
Reproductive hormones (luteinizing hormone [LH], folli-
cle stimulating hormone [FSH] and human chorionic
gonadotropin [hCG)]) are collectively known as gonado-
tropins because they stimulate gonads (testes in male
and ovaries in female). The hormonal activation occurs
through specific ligand-receptor interactions on the sur-
face of the target cells. The LH and hCG utilize a com-
mon receptor encoded by a single copy ~70 kb LHCGR
gene, located at human chromosome 2p21 [1]. LHCGR
has 11 exons and codes for multiple alternatively spliced
species (at least 6) of mRNA. Transcriptional activation
to generate these mRNAs is initiated at multiple sites
spanning a region more than a kilobase upstream of the
first exon [2]. Alternatively spliced mRNAs produce sev-
eral truncated proteins which have the ligand binding
capacity but are ineffective in transducing signals [3-7].
In addition to testis, ovary and placenta, various iso-
forms of LHCGR are expressed in uterine myometrium,
vascular endothelial and smooth muscle cells, adrenals,
brain, skin, lymphocytes, human sperm, macrophages
and in fetal tissues [[8], for a review].
The earliest biochemical evidence on the existence of
cell-free soluble LH receptor was the purification of an
hCG-binding protein, relative molecular mass of 65K
(Mr, 65K) from porcine follicular fluid and was based on
gel filtration followed by affinity chromatography [9]. A
different experimental approach by West and Cooke [10]
demonstrated the secretion of Mr 80-90K hCG-LH recep-
tor complex into the culture media from ligand-induced
rat and mouse leydig cells. Tsai-Morris et al. [11] first
reported the production and secretion of soluble LH
receptor following transient transfection of a naturally
truncated variant of the receptor in COS cells. These data
were independently substantiated using different combina-
tions of in vitro expression systems [12,13], In some stu-
dies, the lack of detection of an actively secreted soluble
form of expressed LH receptor was attributed to misfold-
ing and intra-cellular retention of the expressed protein or
proteolytic degradation of the protein released into the
culture media [13,14]. Moreover, the lack of a secreted
form of the receptor was overcome by co-expression of
hCG with the extra-cellular domain of porcine LH recep-
tor leading to the secretion of a mixture of free as well as
hCG-receptor complex [13].
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Notably, the natural rat Lhcgr variant first described
by Tsai-Morris et al. [11], instead of being secreted, was
retained in the ER prior to degradation [15]. Addition-
ally, the truncated Lhcgr, misrouted the full-length
Lhcgr in ER, thereby decreasing the cell surface expres-
sion of the mature functional receptor. The role of cir-
culating sLHCGR as in inhibitor of LH/hCG functions
by ligand binding has been questioned; instead, a speci-
fic intra-cellular role of truncated receptor in regulating
the cell surface expression of a full-length ligand-bind-
ing Lhcgr has been proposed [15]. Therefore, how a
complex LHCGR protein, embedded within the mem-
brane lipid bilayer, could be secreted as soluble receptor
remained unexplained.
Structurally, LHCGR is similar to thyroid and follicle
stimulating hormone receptors (TSHR and FSHR
respectively). The autoantibody-binding extracellular
domain (ECD; N-terminal 418 amino acid residues) of
TSHR when expressed in CHO cells had a high content
of mannose residues, was misfolded and retained in
cells. However, expression of progressively truncated
carboxy- terminal domains of TSHR in stably trans-
fected CHO cells resulted in the secretion of the TSHR
ECD with an efficiency that was inversely proportional
to the length of the recombinant proteins [16]. These
reports prompted us to generate C-terminally truncated
recombinant variants of LHCGR and examine the
expression of the secreted recombinant proteins in
serum-free medium. Contrary to our expectation, we
have demonstrated here that the release of soluble
LHCGR protein from transfected cells as well as from
placental explants was independent of the length of the
receptor protein and mediated via structurally defined
membrane vesicles.
Methods
Construction of LHCGR cDNA clones
Initially, three LHCGR cDNA clones inserted into the
mammalian expression vectors (30233-0, 30233-1,
30233-2) were created. A cDNA fragment encoding the
N-terminal 318 amino acids of human LHCGR
(CCDS1842.1; UniProtKB/Swiss-Prot P22888) was
obtained by polymerase chain reaction (5’-AAGCTTAT-
GAAACAGCGTTT-3’ and 5’-GGATCCCAGGGTC-
TTGTTAC-3’; forward and reverse primers containing
HindIII and BamHI sites respectively). The PCR ampli-
fied fragment was engineered to have a CTGCAG inser-
tion (corresponding to Leu-Gln, LQ insertion) at
nucleotide position 55-60 (amino acid residues 19-20).
The idea behind this being that the LQ containing poly-
morphic variant in the ‘signal peptide’ appears to
express and function efficiently (2, 4). The resultant
966bp PCR amplified fragment (30233-0) was cloned
into the HindII and BamHI site of p3XFLAG-CMV-14
vector (Sigma Aldrich). The cDNA encoding the first
291 amino acids of LHCGR (30233-1) was created
employing 885 bp PCR fragment (5’-AAGCTTATG-
AAACAGCGTTT-3’ and 5’-GGATCCCTCTTTAGT-
GGGCA-3’, forward and reverse primers respectively).
The cDNA encoding the first 229 amino acid residues
of LHCHR (30233-2) was obtained by PCR amplification
of 699bp fragment (5’-AAGCTTATGAAACAGCGTTT-
3’ and 5’-GGATCCGAGGGTCTTGGGGC-3’, forward
and reverse primers, respectively). To generate 30233-3
(a vector containing the N-terminal 416 amino acids of
LHCGR), a 300bp cDNA (5’-TACTCCTCCA-3’ and
5’-GGCGATCAGC-3’, forward and reverse primers,
respectively) was ligated to the 3’ end (corresponding to
the C-terminus) of 30233-0. The codon optimized DNA
sequences of each clone were verified prior to plasmid
amplification and purification. Plasmid DNA was pre-
pared using Purelink HiPure Plasmid kit (Invitrogen)
and sterile filtered through a 0.22 μm filter.
Cell culture, transfection and expression of recombinant
LHCGR protein in CHO-S cells
One vial of 107 frozen CHO-S cells was added to 30 ml
of pre-warmed serum-free Freestyle CHO medium (Invi-
trogen) containing 8 mM L-glutamine without antibio-
tics in a 125 ml disposable polycarbonate spinner flask
with vented cap (Sigma-Aldrich) and incubated at 37°C,
8% CO2 with 150 rpm stirring. Total cell count and cell
viability were monitored every 24h. A cell viability of
>70% was required in order to continue with the cell
expansion. Cells were subcultured by seeding at a cell
density of 0.3 - 0.5 × 106 viable cells/ml. The cell den-
sity was never allowed to exceed 2 × 106 cells/ml. Fol-
lowing expansion, cells were pooled for measurement of
cell count and viability. The cell viability of expanded
cells before transfection exceeded 95%. Pooled cells
were used to seed fresh flasks of pre-warmed serum free
medium containing 8 mM L-glutamine at a density of
1 × 106 cells/ml in a minimum of 60 ml per 125 ml
spinner flask prior to DNA transfection.
75 μg (75 μl) of filter sterilized plasmid DNA was used
for each transfection of 1 × 106 cells per ml in a total
volume of 60 ml of cells. The sterile DNA was first
diluted into Opti-Pro SFM (Invitrogen) to a total
volume of 1.2 ml and mixed. In a separate tube, 75 μl of
FreeStyle Max Transfection Reagent (Invitrogen) was
added to Opti-Pro SFM to a total volume of 1.2 ml and
mixed gently by inverting the tube. The diluted Free-
STyle MAX Transfection Reagent was added to the
diluted DNA solution to obtain a total volume of 2.4 ml
and mixed gently. As a negative control (no DNA and
no FreeStyle MAX Reagent), 1.2 ml of Opti-Pro SFM
was mixed with 1.2 ml tissue culture medium. After
incubation at room temperature for 10 minutes, the
Chambers et al. Reproductive Biology and Endocrinology 2011, 9:64
http://www.rbej.com/content/9/1/64
Page 2 of 15
DNA-FreeStyle MAX mix was added to the CHO sus-
pension culture and the flasks were transferred to the
incubator (37°C, 150 rpm, 8% CO2). Following transfec-
tion, aliquots (4ml) was removed from each transfection
every 24h up to day 7 (D7). No extra tissue culture
medium or passaging of cells was carried out after
transfection. Both cell density and cell viability for each
culture were recorded. Aliquots were collected in sterile
15 ml conical tubes and spun at 700 rpm in a Beckman
J6 centrifuge using a JS-4.2A rotor for 6 minutes at
room temperature. To monitor any secretion of proteins
from the cells, the tissue culture medium (supernatant)
was carefully removed to another sterile tube after cen-
trifugation, leaving the last 200 μl so as not to disturb
the cell pellet. Supernatents were stored at -20°C. Cell
pellets were washed three times with sterile PBS (4°C)
to remove residual tissue culture medium and transfec-
tion reagents, aspirated and stored at -20°C.
Placenta explant culture
This study was approved by the local ethics committee
of Planned Parenthood, Fannin Health center, Houston,
Texas and written consent was obtained from patients
before the collection of samples. Placental tissue was
obtained from patients undergoing elective termination
of pregnancy with gestational age range of 9-12 wks
(gestational age was determined by ultrasound measure-
ment of biperietal diameter or crown-rump length).
Immediately after collection, the placenta tissue was
rinsed with sterile PBS and sequentially washed (10-12
times) to remove traces of blood. The tissue was dis-
sected in a sterile cell culture hood to produce small
pieces of placental explants (20-50 mg in weight,
approximately 0.5-1.5 mm) and was resuspended in
serum-free culture medium. The suspension was trans-
ferred to disposable sterile spinner flask and was cul-
tured at constant stirring speed 150 rpm under 8% CO2
up to 48h.
Protein extraction, Western blots and quantitative
analysis of protein expression
Protein extraction from cultured cells was carried out
using hypotonic buffer (10 mM Tris-HCl, pH7.5 con-
taining 25 mM EDTA, 25 mM, NaF, 1 mM Na3VO4,
and EDTA-free protease inhibitor mix [Sigma-Aldrich]).
Detergent extraction of cell culture pellets following
hypotonic lysis was carried out with lysis buffer (25 mM
Hepes pH 7.5, 150 mM NaCl, 1% igepal CA-630
[Sigma-Aldrich], 10 mM MgCl2, 1 mM EDTA, 25 mM
NaF, 1 mM Na3VO4, and EDTA-free protease inhibitor
mix [Sigma-Aldrich]. This sequential extraction method
was employed to obtain a predominantly cytosolic extrac-
tion (via hypotonic lysis) and a predominantly membrane
extraction (hypotonic followed by detergent lysis).
Extraction of placental villous tissue was performed using
either T-PER reagent alone [Perbio, Helsinborg, Sweden]
or T-Per containing 25 mM bicine buffer pH 7.6
[Thermo Fisher Scientific].
Western blot analysis was as described [17,18]. Pri-
mary and secondary antibodies used were as follows:
anti-human LHCGR mouse monoclonal antibody [LHR-
29, ATCC clone CRL2685]; anti-FLAG monoclonal anti-
body [Sigma]; anti -b Actin, clone AC-15 [Sigma] and
goat anti-mouse IgG (H+L) HRP-conjugated [Chemicon
International Inc., CA, USA]; mouse control IgG
[Sigma]. The antibody concentrations used for Western
blots were: LHR-29 diluted to 1 μg/ml; anti-FLAG at
1:1000 dilution and anti-mouse IgG-HRP at 1:10,000 in
the incubation medium. The epitope which the LHR29
monoclonal antibody recognizes has been mapped to a
region between amino acids 227 to 289 of the LHCGR
ECD (unpublished data).
Protein deglycosylation
Five times concentrated N-Glycanase Reaction Buffer
(100 mM sodium phosphate pH 7.5, 0.1% sodium
azide); Denaturation solution (2% SDS, 1 M b-mercap-
toethanol); Detergent Solution (15% NP-40 solution);
Endo H and PNGase F (glycerol-free) were obtained
from Prozyme [San Leandro, California, USA]. Accord-
ing to vendor’s protocol, both Endo H and PNGase
F were added to a final concentration 50 mU/ml and
50 U/ml, respectively. Samples were incubated at 30°C
for 16 h and reactions were terminated by adding
SDS-PAGE loading buffer.
Microvesicle purification from culture supernatants
The placenta explant cultures were collected at 24h and
48h. The explant tissues and the cell debris were first
pelleted by centrifugation at 3000 × g for 15 min. The
supernatant was re-centrifuged at 14000 × g for 15 min
and two-thirds of the clear supernatant from the top of
each tube was transferred to new tubes prior to the pur-
ification of microvesicles by two alternative methods;
ultrafiltration [19] or ultracentrifugation [20,21]. For
ultrafiltration, the vivaspin nanomembrane concentra-
tors [Vivasin 500 Sartorius Inc., Goettingen, Germany]
were washed twice with 600 μl PBS (with centrifugation
at 300 × g) for 5 min to remove glycerol and other pre-
servatives. Subsequently, 600 μl of the clear culture
supernatant was centrifuged in each concentrator col-
umn at 6000 × g for 10 min at 4°C. This process was
repeated and the combined retanate was then mixed
with EDTA-free protease inhibitor mix (Sigma Aldrich)
and stored at -20°C. Alternatively the culture superna-
tant was centrifuged at 10000 × g [L8-70M ultracentri-
fuge, Beckman Coulter, Inc. CA; 70.1 Ti rotor] for 1h
and the pellet was resuspended in PBS containing
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EDTA-free protease inhibitor mix ]Sigma-Aldrich]
before storage at -20°C.
Staining of microvesicles and immune-electron
microscopy
For negative staining, grids were incubated at room
temperature for 10 min with 25 μl of 2% uranyl acetate
and examined by electron microscopy [Jeol 1200EX
TEM operating at an acceleration voltage of 80 kV]. For
immuno-labelling, 10 μl of microvesicles suspension was
dropped onto a 200 mesh nickel Formvar/Carbon
coated grid [Agar Scientific-S162N] and incubated for
40 min in a humid box at room temperature. A drop of
2% paraformaldehyde (PFA) in 0.1 M phosphate buffer,
pH7.2 was added to each grid. Following PFA, grids
were treated sequentially with 0.15% glycine, 1% BSA in
phosphate buffer followed by primary antibodies (anti-
LHCGR, LHR29 or anti-FLAG monoclonal antibodies
or mouse IgG, diluted 1:10 in phosphate buffer with 1%
BSA) for 30 min at room temperature. Unbound pri-
mary antibodies were removed by rinsing with 0.1%
BSA in phosphate buffer four times, 2 min each time.
The grids were labelled with secondary antibody conju-
gated with 10 nm colloidal gold [Clone M2, Sigma-
Aldrich] for 1h at room temperature in a humid box
and then washed multiple times with phosphate buffer
before fixation using 1% glutaraldehyde in 0.1 M phos-
phate buffer for 5 min at room temperature. Following
removal of excess glutaraldehyde, grids were washed six
times with distilled water for 1 min each time prior
to negative staining with 2% aqueous uranyl acetate for
1 min. All experiments were done in duplicate. Samples
were examined in a Jeol 1200EX transmission electron
microscope and images were captured and stored.
Densitometry and data analysis
Densitometry of autoradiograms and data analysis were
carried out as described [17,18]. In the majority of cases
the analyses used b-actin as an internal control for com-
puting the experimental values. However, in some
experiments (see ‘Results’ below), where the b-actin
failed to reflect the yield of LHCGR in the supernatant
fraction, a Mr 63K membrane protein, stained using
Coomassie blue following Western blot, was used as an
internal standard to measure the corresponding LHCGR
protein. A value for the level of significance (P-value)
was calculated using the Poisson statistic. P < 0.05 was
considered significant.
Results
Expression of LHCGR recombinant proteins in CHO cell
suspension culture
Chinese hamster ovary suspension (CHO-S) cells grown
in serum-free medium at a cell density of 106 cells per
ml were transfected with mock or with one of three
LHCGR recombinants; LHCGR-229, LHCGR-291,
LHCGR-318 (Figure 1a) and the cell density and cell
viability were recorded for up to seven days post-trans-
fection. The recombinant LHCGR- 418 has a part of the
first trans-membrane domain of the receptor (Figure 1a)
and was transfected separately in subsequent experi-
ments (data not shown). Exponential cell growth
resulted in a cell density of 3.5 × 106/ml and 2.4-3.1 ×
106/ml in mock and DNA transfected cultures, respec-
tively, at day three (D3), remained stable until day four
(D4) and began to deccline at day five (D5) (Figure 1b).
Notably, the cell density dropped significantly on D7
compared to that on D3 in mock (P = 0.02), recombi-
nants R1- (P = 0.021), R2- (P = 0.007) and R3- (P =
0.038) transfected cells. Unlike the cell density, the cell
viability was highest on D1, and mean cell viability
decreased gradually; D3 (90.2%), D4 (88.7%), D5 (88.2%),
D6 (88.2%) and D7 (77.2%). However the decrease in
cell viability during the course of the experiment was
not significant (P ≥ 0.10 on D7).
In order to examine the expression of recombinant
LHCGR expression, samples were aliquoted from each
transfection including corresponding control cultures at
24-hr intervals for up to seven days (D7). To distinguish
the cytoplasmic soluble LHCGR (sLHCGR) from the
cell membrane-associated receptor protein, the cells
were first lysed in hypotonic buffer. Following hypotonic
extraction, the cell pellet was subject to equal volume of
detergent (Triton) lysis to recover the membrane-bound
LHCGR recombinants. The cumulative expression at
each time point for each recombinant was expressed as
sum of the products in hypotonic and detergent lysates.
The most obvious results from these experiments
were that all three recombinants were expressed at high
levels until 72h following transfection (D3) and there
was a dramatic reduction in expression on D4. Quanti-
tatively, cytoplamic sLHCGR expression for R1-318, R2-
291 and R3-229 on D4 was reduced by 7.3-, 5.3- and
2.5-fold respectively compared to that on D3 post-trans-
fection (Figure 2a and 2c). Similarly, analysis of the
membrane-associated (detergent lysis) LHCGR showed
that the production from R1-318, R2-291 and R3-229
on D4, compared to D3, was reduced by 13-, 21- and
18.8-fold, respectively (Figure 2b and 2d). Moreover,
when analysis was extended to the cumulative (hypo-
tonic plus detergent) LHCGR expression, the R1-318,
R2-291 and R3-229 on D4, compared to D3, was
reduced by 8.6-, 9.9- and 6.2-fold, respectively. Taken
together, these results demonstrate that the LHCGR
recombinant proteins were synthesized abundantly dur-
ing the first three days following transfection and that
the production or accumulation was signifiantly down
regulated from D4 to D7.
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Secretion of sLHCGR into the culture medium
The results shown in Figure 2 demonstrated that irre-
spective of the length of the recombinant protein, the
maximal expression of the LHCGR recombinants
occurred within first 48h post-transfection. A logical
extension of these data is that should there be any
secretion of these proteins into the culture medium, it
might be detected by analysing the corresponding cul-
ture supernatants. To address this, the cell culture
supernatants from mock and experimental samples at
24h and 48h were concentrated by ultra-filtration (see
Materials & methods) and analysed by resolving the
proteins via polyacrylamide gel electrophoresis under
denaturing conditions (SDS-PAGE). The data shown in
Figure 3a demonstrate that while no LHCGR could be
detected at 24h, all three recombinants were barely
detectable in culture supernatants taken at 48h post-
transfection (Figure 3b). The lack of signal in 24h super-
natant was unexpected because with the exception of
LHCGR-229 (P = 0.001), the cumulative cellular expres-
sion (hypotonic plus detergent) of LHCGR-318 (P =
0.15) and LHCGR-291 (P = 0.58) at 24h were not signif-
icantly different from those at 48h. To examine whether
longer incubation introduced cellular stress resulting in
the secretion of sLHCGR, the culture supernatants from
D2, D6 and D7 were analysed. The data presented in
Figure 3c show that, contrary to our expectation, the
highest secretion of sLHCGR was at D6 and the secre-
tion at D2 and D7 was comparable. Further analysis of
the culture supernatants revealed that sLHCGR secre-
tion reached a peak on D4 and remained high until D6
(Figure 3a-d).
The amount of secreted recombinant LHCGR-318,
LHCGR-291 and LHCGR-229 at D4 (Figure 3b-d and
3e), was 26.9%, 37.4% and 24.2% respectively (Figure 3f),
compared to their highest cumulative cellular expression
on D1 or D2 (Figure 2). Additionally, the amount of
LHCGR-318, LHCGR-291 and LHCGR-229 in the
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culture supernatant at D4 was 7-, 11.5- and 4-fold,
respectively, when compared with corresponding cellular
expression on D4 (Figure 2 and Figure 3e and 3f). Simi-
lar results were obtained where secretion of LHCGR-
418 into the medium was maximum on D4 (data not
shown). The cellular expression of the recombinants
was highest on D2 and subsequently declined. And yet,
the amount of protein secreted on D4-D6 was signifi-
cantly higher than the total protein produced by the cell
(intracellular) on D4-D6 (Figure 3f). This paradoxical
observation could be explained assuming that the cellu-
lar microvesicles accumulated up to D3, were abruptly
released into the media between D3 and D4. Once
released, the cellular production of the recombinant
protein was almost shut down and the microvesicle-
bound LHCGR proteins underwent gradual proteolytic
degradation on D5 and D6 before disappearing on D7.
Interestingly, the cell density being high on D3 and D4,
began declining afterwards (Figure 1b).
Secreted LHCGR proteins are glycosylated and folded
The level of glycosylation of recombinant LHCGR
proteins was examined by in vitro deglycosylation with
peptide N-glycosidase F (PNGase F) and endopeptidase
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H (Endo H). The PNGase F, an amine oxidase, cleaves
between asparagine and N-acetylglucosamine (GlcNac)
releasing high mannose, hybrid and complex oligosac-
charides from N-linked glycoproteins. Therefore, PNGase
has the capacity to remove all N-linked oligosaccharides
from glycoproteins. EndoH primarily releases high man-
nose-type from N-linked glycoproteins by cleaving
between two core GlcNac of high mannose chains. The
recombinant LHCGR-318 has six glycosylation sites
whereas LHCGR-291 and LHCGR-229 proteins each
have three sites (Figure 4a). All three recombinants were
fully glycosylated in CHO cells and were susceptible to
both PNGase F and EndoH (Figure 4b). However, a frac-
tion of LHCGR-318 and LHCGR-291 were resistant to
both enzymes. Notably, these non-glycosylated (glycosi-
dase-resistant) species of LHCGR-318 and LHCGR-291
were released from cells by hypotonic lysis indicating
that they are soluble cyoplasmic proteins (indicated by
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arrows in Figure 2a). Moreover, these proteins, despite
being soluble were not secreted into the media (Figure 2a
and Figure 3b-d). We conclude that the majority of the
recombinant LHCGR was glycosylated and that this frac-
tion, irrespective of membrane or cytoplasmic associa-
tion, was secreted from the cells, whereas, a minor
fraction of the recombinant protein devoid of N-linked
glycans, was not released into culture medium. Irrespec-
tive of the level of glycosylation, the recombinant
LHCGR proteins migrated faster under non-reducing
conditions compared to reducing conditions when disul-
phide bonds were broken (Figure 4c) suggesting that
folding of the recombinant LHCGR was independent of
glycosylation.
Selective release of proteins into the culture medium
Three critical observations prompted further investiga-
tion on the secretion of LHCGR into the culture med-
ium; The abrupt release of sLHCGR on day 4 post
transfection when cellular synthesis of the proteins
reduced significantly (Figure 2c and 2d); failure to detect
the cytoplasmic sLHCGR species that were resistant to
deglycosylation in the culture medium (Figures 3 and 4)
and quantitative reduction of b-actin secretion in the
45
37
32
20
45
20
15
M r
Figure 4 Patterns of glycosylation of cell-associated and secreted LHCGR recombinant proteins. a), the relative position of the
glycosylation sites in the three recombinants; b), the LHCGR 229-318 residue proteins from transfected cell extracts (lane 1-9) as well as
concentrated culture supernatants (lanes 10-18) at 96h following transfection were digested with Endo-H and PNGaseF prior to Western blot
analysis as described; notably the protein isoforms resistant to deglycosylation by both enzymes were not secreted; c), both unglycosylated and
glycosylated LHCGR 291 and LHCGR 318 migrate faster under non-reducing (UR) compared to reducing (R) conditions suggesting that folding of
the proteins is independent of glycosylation. Lanes 1-3 are longer exposure of lanes 4-6.
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supernatant (Figure 3a-d) which suggested selective
secretion of the cellular proteins (Figure 3). To investi-
gate these observations, the protein composition of the
cell culture supernatant at D1 and D4 was first com-
pared with that of untransfected CHO cells. The data
shown in Figure 5a, indicate that a large number of pro-
teins (ranging from Mr 10K to 250K) were selectively
lost or enriched in the supernatant (Figure 5a). A
further investigation comparing the supernatant frac-
tions from D1-D7 with their respective total cellular
proteins revealed that the differential release of cellular
proteins into the culture supernatant began on D1 and
continued to increase until D7 (Figure 5b). The resolu-
tion of proteins from the culture medium through an
alternative gel system (Figure 5c) showed that some pro-
teins were enriched (indicated by dark arrows) while
others were depleted (indicated by light arrows) in the
supernatant. This selective secretion of the proteins was
independent of the recombinant LHCGR expression
since the protein profile of the supernantants from
Figure 5 Selective secretion of proteins from transfected cells through microvesicles. a), the whole cell extracts (lane 2, Cont), the culture
supernatants (D1 and D4) following transfection with LHCGR 291 cDNA were centrifuged at low and high speed to remove the cell debris and
subsequently concentrated prior to electrophoresis in 4-12% Bis-Tris polyacrylamide gels; b), same as a) except the medium concentrated from
LHCGR 291 cDNA transfection from D1-D7 are shown; c), shows that proteins secreted from the mock transfected as well as cDNA transfected
cells are similar, the dark and light arrows indicate quantitative enrichment and reduction of proteins secreted in the medium respectively; d),
electron micrographs of D4 culture supernatents concentrated by ultracentrifugation (left panel) and by ultrafiltration (right panel). The
microvesicle shown in the inset is a 12-fold magnification of that seen at the right-bottom corner of the figure, below the inset.
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mock-transfected cultured cells was similar to that from
DNA- transfected cells (data not shown).
The release of recombinant LHCGR is mediated via
microvesicles
The amount of total recombinant LHCGR on D4 and D5
in the supernatant was 4-12 fold higher than the corre-
sponding total cellular proteins (Figure 3d-f), suggesting
that the majority of protein synthesised on Days 1-3 was
secreted on Days 4 and 5. The observation of specific
secretion led us to hypothesise that the secretion might
be active, involving sub-cellular organelles. To test this
hypothesis, a three step centrifugation procedure was
adopted whereby the highly clarified culture supernatant
was subjected to ultracentrifugation in order to pellet any
subcellular particles. As an alternative method, clarified
culture supernatant was also concentrated by ultrafiltra-
tion (see Materials and Methods). Western blot analysis
of the concentrated supernatant and the pellet following
ultracentrifugation showed that only the pellet contained
the LHCGR. Standard microscopy revealed subcellular
particles with no detectable intact cells in the resus-
pended pellet (data not shown). Electron microscopy on
the material from the pellet following ultracentrifugation
revealed distinct subcellular particles. Based on the size
of these particles (50-200 nm), the sLHCGR recombi-
nants appear to have been released as components of
these microvesicles (Figure 5d).
Microvesicle-mediated release of sLHCGR from human
placenta explants at early pregnancy
To investigate whether release of sLHCGR is unique to
cells transfected with LHCGR recombinants, dissected
placental explants from early pregnancy (9 and 10 wks
of gestation) were cultured up to 48h under identical
conditions in serum-free medium as described above.
Aliquots of culture medium were collected after 12h,
24h and 48h incubation. Analysis of the proteins from
concentrated culture supernatant and the control pla-
cental extract (uncultured) by SDS-PAGE revealed
quantitative and selective release of some proteins in the
supernatant (Figure 6a). Electron microscopy analysis of
the supernatant revealed the release of 50-300 nm vesi-
cles from cultured placental explants (Figure 6b). Wes-
tern blots performed on extracts from placenta and
microvesicles with LHR29 monoclonal antibody against
LHCGR (the epitope is mapped between 229-291 amino
acids) showed that Mr 52K, 65K and 90K proteins were
associated with microvesicles (Figure 6c and 6d). The
absence or quantitative reduction of 37K, 65K, 85K and
high molecular mass LHCGR isoforms in the explant
supernatants compared to the control placenta (Figure
6c) confirmed selective association of LHCGR protein
with microvesicles released from the placenta. These
results provide evidence that the release of LHCGR
from transfected cells via microvesicles is not unique
and that natural, membrane-bound full-length LHCGR
and truncated LHCGR variants are also released from
placental tissues in this manner.
Not all microvesicles from the placenta contain LHCGR
We sought another line of evidence to verify that the
microvesicles released into the culture supernatant con-
tain the LHCGR protein. This was achieved by immu-
nostaining the microvesicles with LHCGR-specific
(LHR29) primary antibody followed by anti-mouse IgG
gold-labeled secondary antibody (Figure 7b &7d). As a
control (Figure 7a &7c), mouse IgG was used as a pri-
mary antibody followed by anti-mouse IgG gold-labeled
secondary antibody. Unlike the microvesicles derived
from transfected CHO cell culture supernatant (Figure
7b), only 30-40% microvesicles released from human
placenta (Figure 7d) were immunostained with LHCGR-
specific antibody. The LHR29 monoclonal antibody
recognizes an epitope that is between amino acid resi-
dues 227-289 of LHCGR at the N-terminus (see Materi-
als & Methods). As an additional control the
microvesicles from LHCGR 291 transfected cells (day 4)
and placental explants (PES-24h) supernatants were first
reacted with anti-FLAG mouse monoclonal primary
antibody followed by anti-mouse IgG gold-labeled sec-
ondary antibody. As would be expected, only those
microvesicles derived from transfected cells reacted with
anti-FLAG antibody (data not shown). These experi-
ments confirm that the LHCGR protein is integral to
the microvesicles released into the culture supernatant
for both recombinant transfectants and cultured placen-
tal explants and further show that only a fraction of the
microvesicles released from the placenta contain
LHCGR.
Discussion
In this manuscript, we demonstrate that the secretion of
soluble LHCGR from transfected cells as well as from
placental tissues is independent of the size of the recep-
tor and is mediated via microvesicles. Since microvesi-
cles are also released from mock-transfected cells and
only a portion of placental explant microvesicles stain
positive for LHCGR, the mechanism of secretion is not
specific to the LHCGR. The data presented here support
previous work describing the abundant extracellular
appearance of LH receptor and its natural variants lack-
ing either transmembrane or intracellular domains, or
both, following transfection with cDNA [11,12]. It is
noteworthy that these authors speculated that the
secreted receptor proteins could be packaged in mem-
brane vesicles [12]. Additionally, while biochemical [9]
and cell biological [10] studies demonstrated the release
Chambers et al. Reproductive Biology and Endocrinology 2011, 9:64
http://www.rbej.com/content/9/1/64
Page 10 of 15

Figure 6 The microvesicles from placenta explants contain both full-length and truncated LHCGR isoforms as well as selectively
enriched proteins. a), the placenta tissue extracts (Placenta) as well as proteins extracted from placenta explant microvesicles (PES) released
into the culture medium at 24h (PES-24h) and 48h (PES-48h) were separated in 4-12% polyacrylamide SDS gels. The selective loss of proteins of
Mr 50K-20K in the microvesicle fraction is indicated by a bracket; b), microvesicles purified by ultracentrifugation of the culture medium were
examined by transmission electron microscopy; c) and d), microvesicle proteins include LHCGR as shown by c), Western blot probed with LHR29
monoclonal antibody and subsequently d), stained with coomassie blue.
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of LH receptor and hormone-receptor complex, our cur-
rent data in conjunction with recent reports on the con-
stitutive secretion of microvesicles from placenta
throughout the human pregnancy [22], provide the pos-
sible mechanistic basis of the secretion of LHCGR from
cells and tissues.
Questions have been raised regarding the conflicting
results on LH receptor secretion described in the
literature. In the light of the data presented in this
manuscript, two explanations can be proposed that
together might account for this discrepancy. Firstly, the
methods used for in vitro expression and detection of
the secreted receptor may be factors that affect experi-
mental outcome. Secondly, the duration of experiments
could be crucial. The reports of Tsai-Morris et al., and
VuHai-LuuThi et al., [11,12] both describe clear-cut
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Figure 7 Immuno-electron microscopy of microvesicles. The purified microvesicles from LHCGR 291 cDNA transfected culture supernatant at
day 4 (a & b) and placental explants PES-24h (c & d). In a & c (control), the microvesicles were reacted with non-specific mouse IgG and in b &
d (LHR29), the primary antibody was LHR29 monoclonal antibody. The secondary antibody in each case was anti-mouse IgG gold-labeled
antibody.
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secretion of the soluble LH receptor proteins where
experiments were carried out using transient transfec-
tion of cells (via calcium phosphate) and by assaying for
the soluble LH receptor via ligand-binding assays and by
Western blot. The method of transient expression
[11,12] instead of stable cell lines [15,23], detection of
the soluble receptor by immunoprecipitation [15]
instead of ligand-binding assays might therefore have
influenced the different experimental outcomes
described by these groups. The duration of experiments
could be pertinent to the failure to detect soluble LH
receptor. Our data show that receptor expression, mea-
sured by Western blot on supernatants concentrated by
ultrafiltration, following 72h of transfection, was barely
detectable (Figure 3). Indeed, immunoprecipitation of
48h and 72h transfected supernatants with anti-FLAG
monoclonal antibody failed to detect sLHCGR when the
blots were probed with anti-LHCGR monoclonal anti-
body (data not shown). Therefore, a combination of the
methods and biochemical conditions of in vitro expres-
sion of LH receptor, sensitivity of the assay detecting
soluble receptor and the duration of the experiment
together could explain the conflicting data in the
literature.
Direct translocation of the cytoplasmic receptor iso-
forms across the plasma membrane or protease cleavage
of membrane-bound extracellular domains are the
mechanisms that have been proposed for circulating
soluble receptors [24]. We demonstrate that LHCGR is
released from transfected cells and placental explants
packaged in microvesicles. Such secreted proteins
released from tissues into the extracellular space fail to
exhibit typical N-terminal secretory signal sequences as
well as post-translational modifications necessary for
traffic through Golgi/ER [25]. Human tissues under oxi-
dative stress [26], following cellular activation such as
p53 [27] and apoptosis release microvesicles ranging
from relatively smaller (50-150nm) exosomes and
plasma membrane-coated microparticles (100nm-
1000nm), which represent fragments of cell membranes
[28-32]. It should be noted however, that while the
structural and immune-electron microscopic data indi-
cate that released microvesicles could represent exo-
somes, future gradient density and biochemical analyses
would be needed to confirm this.
The pleiotropic effects of microvesicles in inter-cellu-
lar communications have been intensely investigated in
recent years. Given that microvesicles contain mem-
brane proteins, mRNAs, miRNAs, growth factors, cyto-
kine and chemokine receptors, it has been proposed
that these circulating vesicles form a storage pool of
bio-effectors or macromolecules for long-distance trans-
cellular signaling/adhesion in endothelial modifications,
angiogenesis, antigen presentation, immuno-suppression,
differentiation and apoptosis in a variety of patho-phy-
siological conditions including cancer [20,21,33-37].
Human placental syncytotrophoblasts constitutively
secrete microvesicles throughout the pregnancy.
Immune activation, immune-suppression by Fas-FasL-
mediated apoptosis at the fetal-maternal interface and
systemic vasculo-endothelial damage by microparticles
and exosomes released from the placenta are emerging
as modes of immune and vascular regulation in human
pregnancies [22,38,39]. Our data showing that microve-
sicles released from the human placental explants con-
tain full-length as well as truncated LHCGR raises the
possibility that these vesicle-associated receptors, cap-
able of binding LH and hCG hormones, may freely cir-
culate in the blood. As such, the circulating membrane-
bound LHCGR could cause reduced hormone bioactivity
and may mediate abnormal activation of tissues through
mobile receptor fusion. We propose that LHCGR-bear-
ing microvesicles neutralize the natural ligands (LH or
hCG) by forming soluble complexes which prevent the
interactions of these hormones with tissue-specific tar-
get receptors. By altering hormone-mediated cellular
activation of target tissues, the secreted, circulating
sLHCGR may act as a physiological modulator of hor-
mone function and/or as an inhibitor of hormone func-
tion that leads to pathology. This might explain the
altered ratios of bioactive to immunoreactive LH or
hCG that are frequently described in patients with hypo-
gonadism [40], poor fertility [41-43], ovarian dysfunction
[42,43], miscarriage [44-46] and other early pregnancy
complications [47]. The possibility that circulating
microvesicles bearing LHCGR might fuse with vasculo-
endothelial or other cell types thereby making fused
cells subject to LH/hCG activation, may be another level
of complication that disrupts cell signaling. There is pre-
cedence for microvesicle-mediated transfer of the trans-
ferrin receptor [48], but whether the horizontal transfer
of LHCGR occurs will require further investigation.
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